TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04937140

Intervention type: DIAGNOSTIC_TEST
Intervention: 14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients
Description: assessment of 14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients and Carotid Doppler ultrasound (for measurement of carotid intima media thickness and detection of plaques)

Intervention type: DIAGNOSTIC_TEST
Intervention: 14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients
Description: assessment of 14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients and Carotid Doppler ultrasound (for measurement of carotid intima media thickness and detection of plaques)
Study: NCT06005662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The proposed study is a double-blind, controlled investigation of the effect of 1 high-dose psilocybin (30 mg) session compared to a very low dose session (1 mg) following standard-of-care buprenorphine induction on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: The proposed study is a double-blind, controlled investigation of the effect of 1 high-dose psilocybin (30 mg) session compared to a very low dose session (1 mg) following standard-of-care buprenorphine induction on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis
Study: NCT04878029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06498388

Intervention type: OTHER
Intervention: Stiffness measurement by visco-elastography
Description: Participant will be asked to put on the study's bra with the help of a female member of the team if necessary and to complete the examination process.

Intervention type: OTHER
Intervention: Stiffness measurement by visco-elastography
Description: Participant will be asked to put on the study's bra with the help of a female member of the team if necessary and to complete the examination process.
Study: NCT06386744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dusquetide
Description: 1.5 mg/mL dusquetide administered as a 4 minute IV infusion, twice per week for 4 weeks
Study: NCT06611423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: AZD3427 SC injection to be prepared using AZD3427 diluent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: AZD3427 SC injection to be prepared using AZD3427 diluent

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AZD3427 Placebo
Description: AZD3427 Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AZD3427 Placebo
Description: AZD3427 Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Description: Dopamine Hydrochloride 50mg/5mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dopamine
Description: Dopamine Hydrochloride 50mg/5mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiolabelled ligand
Description: Injection of radioligand for PET examinations

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Radiolabelled ligand
Description: Injection of radioligand for PET examinations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiolabelled ligand
Description: Injection of radioligand for PET examinations

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Radiolabelled ligand
Description: Injection of radioligand for PET examinations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline solution
Study: NCT06332924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational discussion group
Description: There will be 3 interviews with the motivational interview group, one week apart.
Study: NCT05317923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow Controlled Ventilation
Description: Anesthesia management in patients with subglottic tracheal stenosis with flow-controlled ventilation using an intubation tube with an inner diameter of less than 3 mm
Study: NCT06303024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized combined physical and cognitive intervention
Description: The exercise intervention will be aerobic and performed on a stationary bicycle and will comply with the basic principle of progressive overload. An incremental exercise test until exhaustion on a bicycle ergometer will be applied to determine directly measured VO2-max in order to customize and personalize the training on each patient. The progressive aerobic exercise (PAE) will last 12 weeks with two sessions per week. Continuous training will be alternated with interval training during the program. The intervention included two weekly training sessions. One session will involve continuous exercise initially commencing at 10 min and progressing towards 30 min/session. Ultimately, a computer based cognitive rehabilitation program will be carried out twice a week for 12 weeks, using the Rehacom software. Participants will begin at level 1 on each RehaCom module and advance through the program as dictated by their performance. Each session will be programmed to last 60 minutes.
Study: NCT06437522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT04670510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On-site AE
Description: Participants will attend on-site supervised AE sessions 3 times per week for the first 6 weeks, twice weekly for weeks 7-12; once weekly for weeks 13-18.~All supervised sessions will start and end with 5-minute warm-up and cool-down and will involve exercise on the treadmill, elliptical, and/or bike. During AE sessions, participants will exercise so that their heart rate is approximately 65% of their peak heart rate and gradually increase the intensity of exercise so that their heart rate is between 70 and 85% of their peak heart rate. All participants will wear heart rate monitors and encouraged to exercise in their target heart rate zone. Supervised AE sessions will gradually increase to 50-minutes per session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: At-home AE
Description: Participants will increase at-home AE during the 6-month intervention period with weeks 19-26 occurring entirely at-home. As participants transition to home-based exercise, they will be equipped with a polar heart rate monitor and will be instructed to use this to record average heart rate during each exercise session. On a log sheet, they will record both average heart rate during exercise and average subjective rating of perceived exertion (RPE) during each exercise session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social Engagement (SE)
Description: To control for the social component of the AE intervention participants in the SE group will be invited to attend at total of 25 group meetings over the course of the 6-month study period.
Study: NCT05963022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT04882085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavicefta, Ceftazidime-Avibactam
Description: CAZ-AVI 2.5 g (2 g ceftazidime + 0.5 g avibactam) administered IV as a 2 hour infusion every 8 hours. Dose adjustments are available for participants with CrCL ≤50 mL/min.
Study: NCT06666387

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET-MR examination
Description: PET-MR examination
Study: NCT04882085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Treatment
Description: main treatment expected to be used as either monotherapy or in combination are colistin, tigecycline, fosfomycin, amikacin, and meropenem
Study: NCT04905589

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BetaQuik™
Description: MCT (Medium chain triglycerides)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BetaQuik™
Description: MCT (Medium chain triglycerides)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: WheyBasics
Description: Whey Protein Isolate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Iso-voluminous water
Description: Iso-voluminous Water as comparitor to Betaquik or WheyBasics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iso-voluminous water
Description: Iso-voluminous Water as comparitor to Betaquik or WheyBasics
Study: NCT05285527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiSight 1 Day
Description: Subjects will wear MiSight 1 day lenses for three years.
Study: NCT04688034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-724
Description: Twice a week for 4 hours continuous intravenous administration of OP-724.
Study: NCT05480904

Intervention type: OTHER
Intervention: Neurocognitive (Thinking) Testing
Description: Intelligence: WASI-II 20 min; Sustained Attention:~Conners Continuous Performance Test 3rd ED. 15 min; Memory: California Verbal Learning Test 2nd Ed. 20 min; Visual Selective Reminding 7 min; Processing Speed:Coding/Digit Symbol 3 min; Grooved Pegboard 5 min; Executive Function: Trail Making Test 5 min; Verbal Fluency Test 3 min; Digit Span 5 min; Visuospatial: Rey Complex Figure 10 min; Functional Behavior: CCSS Neurocognitive Questionnaire 5 min.

Intervention type: DIAGNOSTIC_TEST
Intervention: CNS Vital Signs (Thinking) Testing
Description: Attention: Continuous Performance Task 5 mins Processing Speed: Symbol Digit Test 4 mins Executive Function: Shifting Attention 3 min and Stroop Test 5 mins

Intervention type: OTHER
Intervention: Health Questionnaires, Sleep Surveys & Sleep Diary
Description: The participant will be asked to complete the sleep surveys and sleep diary, FACIT fatigue, and CSALTS Pain Survey These questionnaires will take about 29 minutes to complete. The sleep diary is completed at the time the participant wears the sleep device.

Intervention type: OTHER
Intervention: Health Questionnaires, Sleep Surveys & Sleep Diary
Description: The participant will be asked to complete the sleep surveys and sleep diary, FACIT fatigue, and CSALTS Pain Survey These questionnaires will take about 29 minutes to complete. The sleep diary is completed at the time the participant wears the sleep device.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography/EKG
Description: All echocardiograms will be performed using a General Electric VIVID-7. The LV volume, mass and EF will be calculated using the recommendations of the American Society of Echocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function
Description: PFTs will include spirometry, lung volume measurements by body plethysmography and single breath carbon monoxide-diffusion capacity (DLCO).

Intervention type: DEVICE
Intervention: Remote Polysomnography
Description: The Sleep Profiler PSG2/WatchPat device will be used to assess nighttime sleep disorders.

Intervention type: DEVICE
Intervention: Remote Polysomnography
Description: The Sleep Profiler PSG2/WatchPat device will be used to assess nighttime sleep disorders.

Intervention type: DIAGNOSTIC_TEST
Intervention: Physical Function
Description: This is a test of how your heart and lungs respond to exercise.
Study: NCT05400590

Intervention type: PROCEDURE
Intervention: Peripheral venous blood sample
Description: 2.5% of body weight

Intervention type: PROCEDURE
Intervention: Peripheral venous blood sample
Description: 2.5% of body weight

Intervention type: PROCEDURE
Intervention: Conjunctival impression
Description: Collection of the most superficial conjunctival epithelial cells (desquamating) in a non- or minimally invasive, quick and almost painless way, for a biological analysis of ocular surface diseases. Application of a filter paper on the bulbar conjunctiva, under local anesthesia.

Intervention type: PROCEDURE
Intervention: Conjunctival impression
Description: Collection of the most superficial conjunctival epithelial cells (desquamating) in a non- or minimally invasive, quick and almost painless way, for a biological analysis of ocular surface diseases. Application of a filter paper on the bulbar conjunctiva, under local anesthesia.
Study: NCT05362669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS invitation
Description: Behavioral: SMS to invite to cervical cancer screening using HPV self-sampling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone call invitation
Description: Behavioral: Phone call to invite to cervical cancer screening using HPV self-sampling.
Study: NCT04283513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Virazole
Description: Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution. Each vial contains 1.2 g of Ribavirin in 12 mL
Study: NCT04882514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p*17-K4S2
Description: Administer p\*17-K4S2 25 μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: J8-K4S2
Description: Administer a vaccination schedule of J8-K4S2 50μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Rabavert vaccine
Description: Administer the standard Rabavert vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly. The Rabavert vaccine will be used as a control comparator as it has a similar approved dosing schedule to the investigational vaccines.
Study: NCT06128577

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 3-month intensive intervention
Description: Intensive nutritional interventions were as follows: i）Estimation of ideal body weight according to height, calculation of calories by giving 30-40kcal/kg/day according to BMI stratification, and calculation of daily protein requirement at 1.5g/kg/day, which was finally converted into daily dietary recommendations according to the results of the calculations. ii）Distribution of additional protein supplementation by whey protein, each sachet containing 15g of whey protein.~The resistance training program included 5 min of warm-up, 20 min of muscle strength training, and 5 min of slow walking and was performed three times a week. Resistance training involved a dumbbell and sandbags as weights for the major muscles of the upper and lower limbs. In the study, aerobic training is brisk walking or jogging for 30 minutes/day, five times a week.
Study: NCT04712370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional caudal block
Description: Patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space) by the conventional method (blind technique without ultrasound).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided caudal block
Description: Using ultrasound, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided erector spinae plane Block
Description: Under ultrasound guidance, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the transverse process of the second lumbar vertebrae(L2).
Study: NCT04924595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised exercise
Description: Personalised exercise intervention including aerobic and resistance training
Study: NCT05038150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN1
Description: The study drug, SGN1, will be administered as an IV infusion through a dedicated line catheter over 2 hours, which unit dose strength is 0.9-2.0×109 cfu /vial.
Study: NCT05066165

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Arm 1: NTLA-5001
Description: Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Arm 2: NTLA-5001
Description: Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion.
Study: NCT06600490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
Study: NCT05853276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brush DJ app
Description: Brush DJ app is a mobile app which can be freely downloaded. This app was chosen as part of the intervention as it was recognized by the NHS to reduce the risk of gum disease and tooth decay among its users. This app was built around the info given in the public health England Delivering Better Oral Health Toolkit.
Study: NCT05805072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor 60 mg/day, orally on d1,4,8,11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoharringtonine
Description: Homoharringtonine 1 mg/day intravenously on days 3 to 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: cytarabine 10 mg/m2 q12h, intravenously on days 3 to 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclacinomycin
Description: aclacinomycin 10 mg/day intravenously on days 3 to 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: granulocyte colony-stimulating factor 50-600 mcg/m2/day intravenously from days 2 to start, this dosage will be adjusted according to the hemogram,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 20 mg/m2/day intravenously on days 1 to 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 20 mg/m2/day subcutaneously on days 1 to 7
Study: NCT04800159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC Cannabis
Description: Vaporization of cannabis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD Cannabis
Description: Vaporization of cannabis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaporization of placebo
Study: NCT04684979

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cells from HLA-compatible Related
Description: NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cells from HLA Unrelated
Description: NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
Study: NCT05651373

Intervention type: DRUG
Intervention: Prednisone
Description: 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response

Intervention type: DRUG
Intervention: Prednisone
Description: 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: 200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: 200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.

Intervention type: DRUG
Intervention: CertolizumabPegol injection
Description: 200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response.
Study: NCT06371040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19-BCMA Targeted CAR-T Dose 1
Description: 5.0 e5/ kg CD19-BCMA CAR-T positive T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19-BCMA Targeted CAR-T Dose 2
Description: 1.5 e6/ kg CD19-BCMA CAR-T positive T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19-BCMA Targeted CAR-T Dose 2
Description: 5 e6/ kg CD19-BCMA CAR-T positive T cells
Study: NCT05979389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg
Description: Bicalutamide capsules will be prepared from U.S. Pharmacopeia grade powder at a dose of 50 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules of the same color, mass, and appearance to the bicalutamide capsules will be filled using microcrystalline cellulose powder.
Study: NCT05661903

Intervention type: OTHER
Group type: OTHER
Intervention: Spinal Cord Stimulator Set to Minimal/No Stimulation Setting
Description: Patients in this intervention group will have their spinal cord stimulator turned off or to the minimal settings possible.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients in this intervention group will have their spinal cord stimulator turned on to their usual stimulation settings.